Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation
Abstract
Cannabis use disorder (CUD) is a prevalent and chronic psychiatric condition characterized by impaired control over cannabis use, craving, withdrawal symptoms, and continued use despite negative consequences, potentially impairing social and occupational function. Despite increasing legalization and rising global prevalence, no pharmacotherapies are currently approved for CUD, highlighting an important unmet clinical need. Emerging evidence implicates dysregulation of the endocannabinoid system (ECS), particularly CB ₁ receptor signaling and endocannabinoid metabolism, within cortico-striatal and stress-responsive circuits involved in addiction. Large-scale genomic studies further reveal polygenic vulnerability involving loci such as FOXP2 , NPTX1 , CHRNA2 , and PDE4B , suggesting the involvement of neurodevelopmental, glutamatergic, nicotinic, and neuroimmune mechanisms in CUD susceptibility. Together, these findings provide a biologically grounded framework for both therapeutic development and future patient stratification. Early-phase clinical trials of fatty acid amide hydrolase (FAAH) inhibitors, signaling-specific CB ₁ modulators such as AEF0117, cannabidiol (CBD), and selected repurposed agents demonstrate proof-of-concept that mechanism-based interventions can attenuate withdrawal, craving, and cannabis reinforcement. Accumulating evidence also indicates substantial heterogeneity in CUD vulnerability and treatment response, influenced by factors including biological sex, age, psychiatric comorbidities, and patterns of cannabis use. Collectively, current findings support a biologically informed framework for therapeutic development and highlight the importance of understanding CUD heterogeneity. Continued integration of endocannabinoid, genetic, and clinical factors may facilitate future patient stratification, guide mechanism-based therapeutic development, and advance precision psychiatry research in CUD.
Related
- Editorial: Decoding cancer complexity with artificial intelligence and molecular level studies: informatics-driven approaches for therapeutic innovation
- From disrupted routines to sustainable practice: integrating management sciences to navigate the innovation journey of precision imaging
- The Wnt signaling networks in higher-grade meningiomas: from molecular pathogenesis to therapeutic innovation.
- Endometriosis from Initiation to Innovation: Immune Microenvironments, Clonal Lesion Biology, and the Emerging Therapeutic Pipeline
- NRF2 signalling in endometriosis: A hormone-independent axis for fertility-preserving therapeutic innovation
BibTeX
@article{chan2026towards,
title = {{Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation}},
author = {Luo-Wei Chan and I Chen and Sebastian Yu and Yu-Chi Huang},
journal = {Translational Psychiatry},
year = {2026},
month = oct,
doi = {10.1038/s41398-026-04512-6},
url = {https://www.nature.com/articles/s41398-026-04512-6},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Towards precision psychiatry for cannabis use disorder: integrating endocannabinoid neurobiology, genetics, and therapeutic innovation
AU - Luo-Wei Chan
AU - I Chen
AU - Sebastian Yu
AU - Yu-Chi Huang
PY - 2026
DA - 2026/10/07
JO - Translational Psychiatry
DO - 10.1038/s41398-026-04512-6
UR - https://www.nature.com/articles/s41398-026-04512-6
AB - Cannabis use disorder (CUD) is a prevalent and chronic psychiatric condition characterized by impaired control over cannabis use, craving, withdrawal symptoms, and continued use despite negative consequences, potentially impairing social and occupational function. Despite increasing legalization and rising global prevalence, no pharmacotherapies are currently approved for CUD, highlighting an important unmet clinical need. Emerging evidence implicates dysregulation of the endocannabinoid system (ECS), particularly CB ₁ receptor signaling and endocannabinoid metabolism, within cortico-striatal and stress-responsive circuits involved in addiction. Large-scale genomic studies further reveal polygenic vulnerability involving loci such as FOXP2 , NPTX1 , CHRNA2 , and PDE4B , suggesting the involvement of neurodevelopmental, glutamatergic, nicotinic, and neuroimmune mechanisms in CUD susceptibility. Together, these findings provide a biologically grounded framework for both therapeutic development and future patient stratification. Early-phase clinical trials of fatty acid amide hydrolase (FAAH) inhibitors, signaling-specific CB ₁ modulators such as AEF0117, cannabidiol (CBD), and selected repurposed agents demonstrate proof-of-concept that mechanism-based interventions can attenuate withdrawal, craving, and cannabis reinforcement. Accumulating evidence also indicates substantial heterogeneity in CUD vulnerability and treatment response, influenced by factors including biological sex, age, psychiatric comorbidities, and patterns of cannabis use. Collectively, current findings support a biologically informed framework for therapeutic development and highlight the importance of understanding CUD heterogeneity. Continued integration of endocannabinoid, genetic, and clinical factors may facilitate future patient stratification, guide mechanism-based therapeutic development, and advance precision psychiatry research in CUD.
SN - 2158-3188
ER -